Frontotemporal dementia: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• TDP-43 4
• C9orf72 0
• MAPT 2
• TREM2 0
• CSF1R 0
• SOD1 0
• NRF2 0
• AKT 0
• APOE 0
• CDK4/6 0
• GLP-1 0
• HMGB1 0
• LRRK2 0
• MAPK 0
• NLRP3 0
• SIRT1 0
• SNCA 0
• STING 0
• TP53 0

6 of 6+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NINDS · F31

  Characterizing the Role of Gasdermin-Eand Downstream Innate Immune Pathways in Frontotemporal Dementia

  Harvard Medical School· Boston, United States· US$45,214 awarded in fiscal year 2026· until Sept 2029

• NIH NIA · R01

  Synapse repair in Alzheimer's disease and related dementias

  Buck Institute for Research on Aging· Novato, United States· US$785,081 awarded in fiscal year 2026· until Jul 2031

• NIH NINDS · R56

  Unraveling Mechanisms Governing Cell Clearance Deficits in C9ORF72-ALS/FTD

  University of Missouri-Columbia· Columbia, United States· US$539,427 awarded in fiscal year 2026· until Aug 2027

• NIH NIA · R44

  Clinical Evaluation of a Novel [18F] Positron Emission Tomography (PET) Tracer for Differential Diagnosis and Staging of 4R Tauopathies

  Enigma Biomedical Usa, Inc· Knoxville, United States· US$896,719 awarded in fiscal year 2026· until May 2029

• NIH NINDS · R44

  The Therapeutic Development of a Clinical NR1H3 Antisense Oligonucleotide to Reprogram Microglia into a Neuroprotective State in ALS and FTD

  Modulo Bio, Inc.· San Diego, United States· US$847,695 awarded in fiscal year 2026· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  From Stool to Solutions: Diagnose, Decode, Disruptors, and Deliver Interventions for the Human Gut Microbiota in Neurodegenerative Diseases. (GUT-4D)

  Universita Degli Studi del Piemonte Orientale Amedeo Avogadro· Vercelli, Italy· EU contribution €1,568,130· until Sept 2030· 8 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unraveling the impact of RNA-editing in neurodegeneration: a focus on TDP-43 related frontotemporal dementia. (NeuroEDIT)

  Asociacion Instituto de Investigacion Sanitaria Biogipuzkoa· Donostia-San Sebastian, Spain· EU contribution €194,075· until Aug 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  The role of cellular mechanical stress in the pathogenesis of neurodegenerative disorders (NEUROMECH)

  Universita Degli Studi Dell'aquila· L Aquila, Italy· EU contribution €2,647,675· until Dec 2029· 8 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Targeting rogue DNA repair and genomic instability as novel toxicity mechanisms in C9orf72 ALS/FTD (epiC9repair)

  Deutsches Zentrum fur Neurodegenerative Erkrankungen Ev· Bonn, Germany· EU contribution €2,498,905· until Oct 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  Translational METabolomics for NEurodegenerative Diseases dIAgnosis and prognosis (METNEDIA)

  Universita Degli Studi del Piemonte Orientale Amedeo Avogadro· Vercelli, Italy· EU contribution €1,107,210· until Oct 2029· 5 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 492 running projects, newest first. Listed amounts together: US$391.9m + €17.7m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches

  NCT06856850· Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 1
• Organoids 4
• Mendelian Randomization Analysis 10
• CRISPR-Cas Systems 1
• Gene Expression Profiling 4
• Whole Genome Sequencing 3
• Exome Sequencing 1
• Proteomics 17
• Metabolomics 1
• Mass Spectrometry 1
• Flow Cytometry 2
• Immunohistochemistry 1
• Positron-Emission Tomography 28
• Magnetic Resonance Imaging 74
• Machine Learning 18
• Deep Learning 9
• Cohort Studies 34
• Genome-Wide Association Study 13

• Altered Membrane Protein Abundance in the Cerebral Cortex of the JNPL3 Mouse Model of Tauopathy.

  J Proteome Res, Oct 2026

• Integrative synaptosome multi-omics reveals disrupted synapse organization and localized cryptic transcripts in C9ORF72-frontotemporal dementia.

  Acta Neuropathol, Sept 2026

• Data-driven mapping of known and novel fluid biomarker progression profiles in genetic frontotemporal lobar degeneration.

  Alzheimers Res Ther, Aug 2026

• Distinct proteomic CSF profiles in genetic frontotemporal lobar degeneration.

  Brain, Aug 2026

• Proteome-wide Mendelian randomization identifies causal plasma proteins in frontotemporal dementia.

  Neurol Sci, Jul 2026

• Plasma proteome profiling identified biomarkers for the differential diagnosis and molecular staging of neurodegenerative dementias.

  Nat Aging, Jul 2026

• Analytical and clinical validation of a novel proximity extension assay-based plasma biomarker panel in a cohort of prevalent neurodegenerative dementias.

  Alzheimers Res Ther, Jul 2026

• Plasma Proteomic Changes in GRN and C9orf72 Frontotemporal Dementia.

  Eur J Neurol, Jul 2026

• Dementia etiology classification using NULISA plasma biomarkers and machine learning.

  Alzheimers Dement, Jun 2026

• Proteomic analysis in Alzheimer's disease and other dementias: a focus on sex-specific differences.

  Alzheimers Res Ther, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.